Bangor Savings Bank Sells 47 Shares of Eli Lilly and Company (NYSE:LLY)

Bangor Savings Bank decreased its position in shares of Eli Lilly and Company (NYSE:LLY) by 1.4% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,326 shares of the company’s stock after selling 47 shares during the period. Bangor Savings Bank’s holdings in Eli Lilly and Company were worth $2,587,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in LLY. Fuller & Thaler Asset Management Inc. lifted its position in shares of Eli Lilly and Company by 7.0% during the third quarter. Fuller & Thaler Asset Management Inc. now owns 3,054 shares of the company’s stock worth $1,640,000 after purchasing an additional 200 shares during the last quarter. Optiver Holding B.V. purchased a new stake in Eli Lilly and Company in the 3rd quarter valued at about $36,000. Eagle Asset Management Inc. increased its position in shares of Eli Lilly and Company by 37.2% during the third quarter. Eagle Asset Management Inc. now owns 21,274 shares of the company’s stock worth $11,427,000 after acquiring an additional 5,772 shares during the period. Jacobi Capital Management LLC raised its stake in shares of Eli Lilly and Company by 7.7% during the third quarter. Jacobi Capital Management LLC now owns 16,394 shares of the company’s stock valued at $8,805,000 after acquiring an additional 1,168 shares in the last quarter. Finally, GSB Wealth Management LLC raised its stake in shares of Eli Lilly and Company by 10.3% during the third quarter. GSB Wealth Management LLC now owns 800 shares of the company’s stock valued at $430,000 after acquiring an additional 75 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 2,052 shares of the business’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $809.00, for a total transaction of $1,660,068.00. Following the completion of the sale, the insider now owns 98,554,195 shares of the company’s stock, valued at $79,730,343,755. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, major shareholder Lilly Endowment Inc sold 2,052 shares of the business’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $809.00, for a total transaction of $1,660,068.00. Following the completion of the sale, the insider now directly owns 98,554,195 shares in the company, valued at $79,730,343,755. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Johna Norton sold 7,056 shares of the stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $819.38, for a total value of $5,781,545.28. Following the completion of the transaction, the executive vice president now directly owns 25,428 shares of the company’s stock, valued at $20,835,194.64. The disclosure for this sale can be found here. Insiders have sold a total of 762,804 shares of company stock valued at $648,109,138 over the last ninety days. Corporate insiders own 0.13% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Citigroup lifted their target price on Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research report on Tuesday, April 2nd. Jefferies Financial Group boosted their price objective on shares of Eli Lilly and Company from $925.00 to $957.00 and gave the stock a “buy” rating in a research note on Friday, June 7th. Argus lifted their price target on Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a report on Tuesday, May 14th. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Finally, Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average target price of $803.50.

Eli Lilly and Company Stock Down 0.2 %

Shares of LLY opened at $883.88 on Monday. The company has a market capitalization of $840.05 billion, a price-to-earnings ratio of 130.17, a PEG ratio of 1.93 and a beta of 0.36. Eli Lilly and Company has a 52 week low of $434.34 and a 52 week high of $905.45. The stock’s 50-day moving average price is $798.59 and its 200-day moving average price is $729.89. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The firm had revenue of $8.77 billion for the quarter, compared to analysts’ expectations of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The company’s quarterly revenue was up 26.0% on a year-over-year basis. During the same period last year, the firm earned $1.62 EPS. On average, sell-side analysts predict that Eli Lilly and Company will post 13.76 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, June 10th. Shareholders of record on Thursday, May 16th were issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 0.59%. The ex-dividend date of this dividend was Wednesday, May 15th. Eli Lilly and Company’s payout ratio is 76.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.